Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 0102 • ACR Convergence 2021
Differential Impact of TNFi, JAKi and Rituximab on the Outcome of SARS-CoV-2 Infection in RMD Patients
Anne Regierer¹, Rebecca Hasseli², Martin Schaefer¹, Bimba Franziska Hoyer³, Andreas Krause⁴, Hanns-Martin Lorenz⁵, Alexander Pfeil⁶, Jutta Richter⁷, Tim Schmeiser⁸, Anja Strangfeld⁹, Hendrik Schulze-Koops¹⁰, Reinhard Voll¹¹, Christof Specker¹² and Ulf Müller-Ladner¹³, ¹German Rheumatism Research Center, Berlin, Germany, ²Justus-Liebig-University Giessen, Bad Nauheim, Germany, ³Universittsklinikum Schleswig-Holstein, Kiel, Germany, ⁴Immanuel Hospital, Berlin, Germany, ⁵University Hospital Heidelberg Germany, Heidelberg, Germany, ⁶Friedrich Schiller University Jena, Jena, Germany, ⁷Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, ⁸Private Practice, Cologne, Germany, ⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁰Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹¹Department of Rheumatology and Clinical Immunology, University Medical Center, Faculty of Medicine, Albert-Ludwigs-University of Freiburg, Freiburg, Germany, ¹²Evangelisches Krankenhaus, Kliniken Essen-Mitte, Essen, Germany, ¹³JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany
Background/Purpose: Due to the impressive efforts of the global scientific rheumatology community, increasing evidence about inflammatory rheumatic and musculoskeletal diseases (RMD) specific risk factors in…
Abstract Number: 0910 • ACR Convergence 2021
The Association of TNF Inhibitor Use with Incident Hypertension in Ankylosing Spondylitis: Data from the PSOAS Cohort
Jean Liew¹, S. Reza Jafarzadeh², Maureen Dubreuil³, Susan Heckbert⁴, Stephen Mooney⁴, Matthew Brown⁵, Mariko Ishimori⁶, John Reveille⁷, Michael Ward⁸, Michael Weisman⁹ and Lianne Gensler¹⁰, ¹Boston University, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Boston University School of Medicine/ VA Boston, Boston, MA, ⁴University of Washington, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁸Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) is associated with greater cardiovascular (CV) risk than in the general population. The impact of tumor necrosis factor inhibitors (TNFi) on…
Abstract Number: 1309 • ACR Convergence 2021
Impact of the Number of Comorbidities on the Outcome Measures and on the Retention Rate of the First Anti-TNF in Patients with Ankylosing Spondylitis: Two-year Follow-up REGISPONSER-AS
Mara ngeles Puche Larrubia¹, M.Lourdes Ladehesa-Pineda¹, Pilar Font², Alejandro Escudero Contreras³, Eduardo Collantes-Estevez² and Clementina López Medina⁴, ¹Hospital Universitario Reina Sofía, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ³Hospital Universitario Reina Sofía/IMIBIC/Universidad de Córdoba., Cordoba, Spain, ⁴Department of Rheumatology, Reina Sofia Hospital, IMIBIC, University of Cordoba, Cordoba, Spain/ Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France
Background/Purpose: a) To evaluate the impact of the number of comorbidities on the outcome measures after two years of follow-up in patients with ankylosing spondylitis…
Abstract Number: 1884 • ACR Convergence 2021
Real-life Data for the Use of Anti-TNF Treatment in DADA2
Omer Karadag¹, Gizem Ayan², Ozge Basaran³, Ertugrul Cagri bolek⁴, Levent Kilic², Yelda Bilginer⁵, Mehmet Alikasifoglu⁶ and Seza Ozen⁷, ¹Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey, ²Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ³Hacettepe University Pediatric Rheumatology, Ankara, Turkey, ⁴Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁵Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ⁶Hacettepe University, Department of Medical Genetics, Ankara, Turkey, ⁷Hacettepe University Faculty of Medicine, Pediatric Romatology, Ankara, Turkey
Background/Purpose: Deficiency of adenosine deaminase 2 enzyme (DADA2) is an autosomal recessive autoinflammatory disorder associated with ADA2 mutations. ADA2 works as a growth factor and…
Abstract Number: 0103 • ACR Convergence 2021
Patients with Inflammatory Rheumatic Diseases Are at Increased Risk of COVID-19 Related Hospitalization: Data from a Prospective Controlled Cohort Study
Laura Boekel¹, Femke Hooijberg¹, Erik Vogelzang², Maureen Leeuw¹, Sadaf Atiqi¹, Ronald van Vollenhoven³, Alexandre Voskuyl², Irene van der Horst-Bruinsma², Willem Lems¹, Taco Kuijpers², Marieke van Ham⁴, Luuk Wieske², Filip Eftimov², Maurice Steenhuis⁴, Sofie Keijzer⁴, Olvi Christianawati⁴, Floris Loeff⁴, Sander Tas⁵, Mike Nurmohamed⁶, Theo Rispens⁴ and Gertjan Wolbink¹, ¹Reade, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Sanquin, Amsterdam, Netherlands, ⁵Amsterdam UMC, locatie AMC, Utrecht, Netherlands, ⁶Reade; Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands
Background/Purpose: Retrospective studies have suggested that patients with rheumatic diseases may be at increased risk of severe COVID-19 related disease, and that this risk may…
Abstract Number: 0911 • ACR Convergence 2021
Drug Retention of Tumor Necrosis Factors and IL-17 Inhibitors in Axial Spondyloarthritis: A Multi-Center Comparative Analysis
Thibaut Delépine¹, Peggy PHILIPPE², Emeline CAILLIAU³, Eric HOUVENAGEL⁴, Tristan Pascart⁵, Xavier DEPREZ⁶, Rene-Marc FLIPO⁷ and Jean-Guillaume LETAROUILLY², ¹Lille University Hospital, Lille, France, ²Rheumatology Department, University Hospital of Lille, Lille, France, ³Assessment of Health Technologies and Medical Practices Department, University Hospital of Lille, Lille, France, ⁴Rheumatology Department, Lille Catholic Hospitals, Lomme, France, ⁵Groupement Hospitalier de l'Institut Catholique de Lille, Lomme, France, ⁶Rheumatology Department, Hospital Center of Valenciennes, Valenciennes, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) should be considered in patients with active axial spondyloarthritis (AxSpA) despite treatment with nonsteroidal anti-inflammatory drugs. The objective of…
Abstract Number: 1314 • ACR Convergence 2021
Predictive Factors for the Development Acute Anterior Uveitis Attacks in Patients with Axial Spondyloarthritis; The Results of a Longitudinal Analysis
Haluk Cinaklı¹, Elif Ediboglu¹, Eda Otman Akat², Dilek Solmaz³, Gulay Alp¹, Esra Erpek¹, Sercan Gücenmez⁴, Mustafa Ozmen⁴ and Servet Akar³, ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²katip çelebi, izmir, Turkey, ³Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ⁴katip çelebi university, izmir, Turkey
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease mainly affecting sacroiliac joints and spine. Peripheral arthritis, dactylitis and enthesitis may also occur. Acute…
Abstract Number: 1940 • ACR Convergence 2021
Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Jeffrey Curtis¹, Kunihiro Yamaoka², Yi-Hsing Chen³, Levent M Gunay⁴, Naonobu Sugiyama⁵, Carol A Connell⁶, Cunshan Wang⁶, Joseph Wu⁶, Sujatha Menon⁶, Ivana Vranic⁷ and Juan J Gomez-Reino⁸, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Inc, Istanbul, Turkey, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁸Hospital Clínico Universitario, Santiago de Compostela, Spain
Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…
Abstract Number: 0184 • ACR Convergence 2021
Phase III, Randomized Trial Comparing Clinical Outcomes Between Patients with Moderate-to-severe Chronic Plaque Psoriasis Receiving Adalimumab Reference Product (RP) Continuously versus Those Who Switched Between BI 695501 and Adalimumab RP
Alan Menter¹, Dorothy McCabe², Benjamin Lang³, Jennifer Schaible⁴ and Sravan Kumar Eduru⁵, ¹Baylor Scott & White, Dallas, TX, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Boberach, Germany, ⁵(Formerly at) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
Background/Purpose: BI 695501 is a FDA-approved biosimilar to adalimumab RP (AbbVie), and is approved in seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis,…
Abstract Number: 0914 • ACR Convergence 2021
Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from a Phase 3 Multicenter Study
Philip Robinson¹, Stephen Hall², Bengt Hoepken³, Lars Bauer³, Eleni Demas⁴, Mindy Kim⁵ and Atul Deodhar⁶, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Smyrna, GA, ⁶Oregon Health & Science University, Portland, OR
Background/Purpose: Certolizumab pegol (CZP), an Fc-free, PEGylated tumor necrosis factor (TNF) inhibitor, has previously demonstrated efficacy and safety in patients with radiographic (r) and non-radiographic…
Abstract Number: 1323 • ACR Convergence 2021
Uveitis in 406 Patients with Psoriatic Arthritis: Epidemiology, Clinical Characteristics and Relationship with Biological Treatment. Study of a Single University Center
Ana de Vicente Delmás¹, Lara Sánchez-Bilbao², Vanesa Calvo-Río³, David Martinez-Lopez², Alba Herrero-Morant², Eva Galindez-Agirregoikoa⁴, Iñigo Gonzalez-Mazon⁵, Nuria Barroso García⁶, NATALIA PALMOU FONTANA⁷, Ricardo Blanco³ and Miguel Ángel gonzalez-Gay⁸, ¹Hospital Punta de Europa, Cádiz, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario de Basurto, Bilbao, Spain, ⁵H. U. Marques de Valdecilla, Santander, Spain, ⁶Hospital Puerta del Mar, Cádiz, Spain, ⁷UNIVERSITARY HOSPITAL MARQUES VALDECILLA, Santander, Spain, ⁸Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Uveitis is the most common ocular manifestation of psoriatic arthritis (PsA). It has been described that uveitis in PsA tends to be insidious, chronic,…
Abstract Number: 1941 • ACR Convergence 2021
The Risk of Venous Thromboembolic Events in Patients with RA Aged ≥ 50 Years with ≥ 1 Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Christina Charles-Schoeman¹, Roy Fleischmann², Eduardo Mysler³, Maria Greenwald⁴, Cunshan Wang⁵, All-shine Chen⁵, Carol A Connell⁵, John C Woolcott⁶, Sujatha Menon⁵, Yan Chen⁷, Kristen Lee⁷ and Zoltan Szekanecz⁸, ¹Department of Medicine, University of California, Los Angeles, Los Angeles, CA, ²Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Desert Medical Advances, Palm Desert, CA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: ORAL Surveillance (NCT02092467) was a randomized, open-label, non-inferiority, Phase 3b/4 study that assessed the relative risk of major adverse cardiovascular (CV) events (MACE) and…
Abstract Number: 0011 • ACR Convergence 2020
Patients Receiving Cytokine Inhibitors Have Low Prevalence of SARS-CoV-2 Infection
David Simon¹, Koray Tascilar¹, Gerhard Krönke², Arnd Kleyer¹, Mario Zaiss³, Franz Heppt⁴, Christine Meder⁴, Raja Atreya⁵, Entcho Klenske⁵, Peter Dietrich⁵, Abdullah Abdullah⁵, Thorsten Kliem⁵, Giulia Corte⁶, Harriet Morf³, Moritz Leppkes⁵, Andreas Kremer⁵, Andreas Ramming³, Milena Pachowsky⁷, Florian Schuch⁸, Monika Ronneberger⁹, Stefan Kleinert¹⁰, Clara Maier¹¹, Axel Hueber¹², Karin Manger¹³, Bernhard Manger³, Carola Berking⁴, Matthias Tenbusch¹¹, Klaus Überla¹¹, Michael Sticherling³, Markus Neurath⁵ and Georg Schett¹⁴, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Georgia, ³Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Department of Dermatology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Department of Internal Medicine 1, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Gibraltar, ⁷Department of Orthopedic and Trauma Surgery, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁸Rheumatology Clinical Practice Erlangen, Erlangen, Ghana, ⁹Rheumatology Clinical Practice Erlangen, Erlangen, Germany, ¹⁰Rheumatology-Nephrology Practice, Erlangen, Germany, ¹¹Institute of Clinical and Molecular Virology, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ¹²Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany, ¹³Rheumatology Practice Bamberg, Bamberg, Germany, ¹⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Therapeutic interventions for Immune-mediated inflammatory diseases (IMIDs) target cytokines, such as TNF-a, IL-6, IL-17 and IL-23, which are involved in the physiological and pathological…
Abstract Number: 0716 • ACR Convergence 2020
Variations in Adalimumab and Etanercept Dosing in Juvenile Idiopathic Arthritis and Their Effect on Treatment Outcome: A Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry Study
Ruud Verstegen¹, Peter Shrader², Stephen Balevic³, Timothy Beukelman⁴, Colleen Correll⁵, Anne Dennos⁶, Thomas Phillips² and Brian Feldman¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Duke University, Durham, ³Duke University Medical Center, Durham, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵University of Minnesota, Minneapolis, MN, ⁶Duke University, Durham, NC
Background/Purpose: Different dosing strategies of adalimumab and etanercept have been used over the past decade in the treatment of juvenile idiopathic arthritis (JIA). With regards…
Abstract Number: 1054 • ACR Convergence 2020
Treatment with Certolizumab Pegol in Refractory Uveitis Secondary to Inmune-Mediated Inflammatory Diseases. Multicenter Study of 39 Patients
José Luis Martín-Varillas¹, Vanesa Calvo-Río², Lara Sanchez-Bilbao², Inigo Gonzalez-Mazon³, Ignacio Torre⁴, Alvaro García Martos⁵, Amalia Sánchez Andrade⁶, Angel García Aparicio⁷, Juan Ramón De dios⁸, Ana Urriticoechea⁹, Olga Maiz Alonso¹⁰, Raul Veroz¹¹, Andrea García Valle¹², Sergio Rodriguez Montero¹³, Roberto Miguelez¹⁴, Vega Jovani¹⁵, Marisa Hernandez Garfella¹⁶, Arantxa Conesa¹⁷, Olga Martinez Gonzalez¹⁸, Paula Rubio Muñoz¹⁹, Eva Peña Sainz-Pardo²⁰, Miguel Ángel González-Gay²¹ and Ricardo Blanco², ¹Hospital Sierrallana, Torrelavega, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Basurto, Bilbao, Spain, ⁵Hospital del Tajo, Madrid, Spain, ⁶H. Lucus Augusti, Lugo, Spain, ⁷H. Mostoles, Madrid, Spain, ⁸H. Alava, Alava, Spain, ⁹Can Misses, Ibiza, Spain, ¹⁰Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹¹H. Mérida, Mérida, Spain, ¹²H. Palencia, Palencia, Spain, ¹³H. Virgen de Valme, Sevilla, Spain, ¹⁴Toledo, Toledo, Spain, ¹⁵H. Alicante, Alicante, Spain, ¹⁶H. Valencia, Valencia, Spain, ¹⁷H. Castellón, Castellón, ¹⁸H. Salamanca, Salamanca, ¹⁹H. Esperit Sant, Barcelona, Spain, ²⁰H. 12 de Octubre, Madrid, Spain, ²¹Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Infliximab and adalimumab therapy has significantly improved the prognosis of patients with non-infectious refractory uveitis. However, there is not enough evidence for the use…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].